Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention

Seminars in Oncology

Volumn 43, Issue 1, 2016, Pages 65-77

  Umar, Asad ^a   Steele, Vernon E ^a   Menter, David G ^b   Hawk, Ernest T ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Aspirin; Cancer prevention; Inflammation; Non steroidal anti inflammatory drugs (NSAID)

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ACETYLSALICYLIC ACID; CASPASE 3; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKINE; ICOSANOID; LIPOXIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; SIMVASTATIN; SULINDAC; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; GLUCOSE;

CANCER CELL; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CATABOLISM; CEREBROVASCULAR ACCIDENT; COLORECTAL ADENOMA; COLORECTAL CANCER; ENZYME INHIBITION; FAMILIAL COLON POLYPOSIS; GLUCOSE METABOLISM; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; ICOSANOID METABOLISM; IMMUNOMODULATION; INFLAMMATION; META ANALYSIS (TOPIC); PRECANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; ULCERATIVE COLITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELLULAR IMMUNITY; CHEMOPROPHYLAXIS; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION; THROMBOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD PLATELETS; CHEMOPREVENTION; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; EICOSANOIDS; GLUCOSE; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84960416786     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.09.010     Document Type: Review

References (232)

1. M.G. Bousser, P. Amarenco, A. Chamorro, and et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial Lancet 377 2011 2013 2022
2. A.T. Chan, N. Arber, J. Burn, and et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview Cancer Prev Res (Phila) 5 2012 164 178
3. A.T. Chan, and N.R. Cook Are we ready to recommend aspirin for cancer prevention? Lancet 379 2012 1569 1571
4. J. Cuzick, M.A. Thorat, C. Bosetti, and et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population Ann Oncol 26 2015 47 57
5. L.B. Goldstein, and P.M. Rothwell Advances in prevention and health services delivery 2010-2011 Stroke 43 2012 298 299
6. R.E. Langley, and P.M. Rothwell Potential biomarker for aspirin use in colorectal cancer therapy Nat Rev Clin Oncol 10 2013 8 10
7. R.E. Langley, and P.M. Rothwell Aspirin in gastrointestinal oncology: new data on an old friend Curr Opin Oncol 26 2014 441 447
8. P.M. Rothwell Alternate-day, low-dose aspirin and cancer risk Ann Intern Med 159 2013 148 150
9. A.M. Algra, and P.M. Rothwell Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials Lancet Oncol 13 2012 518 527
10. P.M. Rothwell, J.F. Price, F.G. Fowkes, and et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials Lancet 379 2012 1602 1612
11. P.M. Rothwell Aspirin in prevention of sporadic colorectal cancer: current clinical evidence and overall balance of risks and benefits Recent Results Cancer Res 191 2013 121 142
12. R.N. Pinckard, D. Hawkins, and R.S. Farr In vitro acetylation of plasma proteins, enzymes and DNA by aspirin Nature 219 1968 68 69
13. J.M. Macdonald, D.A. LeBlanc, A.L. Haas, and R.E. London An NMR analysis of the reaction of ubiquitin with [acetyl-1-13C]aspirin Biochem Pharmacol 57 1999 1233 1244
14. M.S. Liyasova, L.M. Schopfer, and O. Lockridge Reaction of human albumin with aspirin in vitro: mass spectrometric identification of acetylated lysines 199, 402, 519, and 545 Biochem Pharmacol 79 2010 784 791
15. J. Wang, C.J. Zhang, J. Zhang, and et al. Mapping sites of aspirin-induced acetylations in live cells by quantitative acid-cleavable activity-based protein profiling (QA-ABPP) Sci Rep 5 2015 7896
16. J. Lei, Y. Zhou, D. Xie, and Y. Zhang Mechanistic insights into a classic wonder drug-aspirin J Am Chem Soc 137 2015 70 73
17. E.G. Kovacs, E. Katona, Z. Bereczky, and et al. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals Thromb Res 131 2013 320 324
18. C. Antithrombotic Trialists, C. Baigent, L. Blackwell, and et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
19. Force USPST Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 150 2009 396 404
20. C. Bosetti, V. Rosato, S. Gallus, J. Cuzick, and C. La Vecchia Aspirin and cancer risk: a quantitative review to 2011 Ann Oncol 23 2012 1403 1415
21. A. Bardia, J.O. Ebbert, R.A. Vierkant, and et al. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality J Natl Cancer Inst 99 2007 881 889
22. A.T. Chan, J.E. Manson, D. Feskanich, M.J. Stampfer, G.A. Colditz, and C.S. Fuchs Long-term aspirin use and mortality in women Arch Intern Med 167 2007 562 572
23. E.J. Jacobs, C.C. Newton, S.M. Gapstur, and M.J. Thun Daily aspirin use and cancer mortality in a large US cohort J Natl Cancer Inst 104 2012 1208 1217
24. L.D. Ratnasinghe, B.I. Graubard, L. Kahle, J.A. Tangrea, P.R. Taylor, and E. Hawk Aspirin use and mortality from cancer in a prospective cohort study Anticancer Res 24 2004 3177 3184
25. R.S. Sandler, S. Halabi, J.A. Baron, and et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer N Engl J Med 348 2003 883 890
26. J.A. Baron, B.F. Cole, R.S. Sandler, and et al. A randomized trial of aspirin to prevent colorectal adenomas N Engl J Med 348 2003 891 899
27. R. Benamouzig, J. Deyra, A. Martin, and et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial Gastroenterology 125 2003 328 336
28. J. Burn, A.M. Gerdes, F. Macrae, and et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial Lancet 378 2011 2081 2087
29. R.K. Phillips, M.H. Wallace, P.M. Lynch, and et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis Gut 50 2002 857 860
30. N. Arber, C.J. Eagle, J. Spicak, and et al. Celecoxib for the prevention of colorectal adenomatous polyps N Engl J Med 355 2006 885 895
31. M.M. Bertagnolli, C.J. Eagle, A.G. Zauber, and et al. Celecoxib for the prevention of sporadic colorectal adenomas N Engl J Med 355 2006 873 884
32. R.S. Bresalier, R.S. Sandler, H. Quan, and et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 2005 1092 1102
33. D.J. Kerr, J.A. Dunn, M.J. Langman, and et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer N Engl J Med 357 2007 360 369
34. S.D. Solomon, M.A. Pfeffer, J.J. McMurray, and et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas Circulation 114 2006 1028 1035
35. F.L. Meyskens Jr., C.E. McLaren, D. Pelot, and et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial Cancer Prev Res (Phila) 1 2008 32 38
36. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
37. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
38. E. Kassi, and P. Moutsatsou Glucocorticoid receptor signaling and prostate cancer Cancer Lett 302 2011 1 10
39. T. Van Bogaert, K. De Bosscher, and C. Libert Crosstalk between TNF and glucocorticoid receptor signaling pathways Cytokine Growth Factor Rev 21 2010 275 286
40. C.G. Chapman, and D.T. Rubin The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease Gastrointest Endosc Clin N Am 24 2014 353 365
41. Coxib, traditional NTC, N. Bhala, and et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials Lancet 382 2013 769 779
42. C.E. Eberhart, R.J. Coffey, A. Radhika, F.M. Giardiello, S. Ferrenbach, and R.N. DuBois Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas Gastroenterology 107 1994 1183 1188
43. C.S. Williams, C. Luongo, A. Radhika, and et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas Gastroenterology 111 1996 1134 1140
44. R.N. DuBois, A. Radhika, B.S. Reddy, and A.J. Entingh Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors Gastroenterology 110 1996 1259 1262
45. M. Oshima, J.E. Dinchuk, S.L. Kargman, and et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) Cell 87 1996 803 809
46. M. Oshima, N. Murai, S. Kargman, and et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor Cancer Res 61 2001 1733 1740
47. A. Umar, J.L. Viner, W.F. Anderson, and E.T. Hawk Development of COX inhibitors in cancer prevention and therapy Am J Clin Oncol 26 2003 S48 S57
48. P.C. Chulada, M.B. Thompson, J.F. Mahler, and et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice Cancer Res 60 2000 4705 4708
49. S.M. Fischer, E.T. Hawk, and R.A. Lubet Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention Cancer Prev Res (Phila) 4 2011 1728 1735
50. M.M. Bertagnolli, C.J. Eagle, A.G. Zauber, and et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial Cancer prevention research 2 2009 310 321
51. D.G. Menter, R.L. Schilsky, and R.N. DuBois Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward Clin Cancer Res 16 2010 1384 1390
52. R.N. Dubois Role of inflammation and inflammatory mediators in colorectal cancer Trans Am Clin Climatol Assoc 125 2014 358 372
53. S. Moncada, R. Gryglewski, S. Bunting, and J.R. Vane An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation Nature 263 1976 663 665
54. M.J. Cho, and M.A. Allen Chemical stability of prostacyclin (PGI2) in aqueous solutions Prostaglandins 15 1978 943 954
55. D.G. Menter, S.C. Tucker, S. Kopetz, A.K. Sood, J.D. Crissman, and K.V. Honn Platelets and cancer: a casual or causal relationship: revisited Cancer Metastasis Rev 33 2014 231 269
56. P. Guillem-Llobat, M. Dovizio, S. Alberti, A. Bruno, and P. Patrignani Platelets, cyclooxygenases, and colon cancer Semin Oncol 41 2014 385 396
57. M. Dovizio, S. Alberti, P. Guillem-Llobat, and P. Patrignani Role of platelets in inflammation and cancer: novel therapeutic strategies Basic Clin Pharmacol Toxicol 114 2014 118 127
58. M. Hamberg, J. Svensson, P. Hedqvist, K. Strandberg, and B. Samuelsson Involvement of endoperoxides and thromboxanes in anaphylactic reactions Adv Prostaglandin Thromboxane Res 1 1976 495 501
59. C. Skarke, and G.A. FitzGerald Selective COX-2 inhibitors suppress prostacyclin Clin Ther 36 2014 2120 2121
60. C.D. Funk, and G.A. FitzGerald COX-2 inhibitors and cardiovascular risk J Cardiovasc Pharmacol 50 2007 470 479
61. J. Iwamoto, Y. Saito, A. Honda, and Y. Matsuzaki Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy World J Gastroenterol 19 2013 1673 1682
62. L.M. Lichtenberger, Y. Zhou, V. Jayaraman, and et al. Insight into NSAID-induced membrane alterations, pathogenesis and therapeutics: characterization of interaction of NSAIDs with phosphatidylcholine Biochim Biophys Acta 1821 2012 994 1002
63. D.G. Menter, and R.N. Dubois Prostaglandins in cancer cell adhesion, migration, and invasion Int J Cell Biol 2012 2012 723419
64. D. Wang, and R.N. Dubois Eicosanoids and cancer Nat Rev Cancer 10 2010 181 193
65. N. Yoshida, and N. Aoki Release of arachidonic acid from human platelets. A key role for the potentiation of platelet aggregability in normal subjects as well as in those with nephrotic syndrome Blood 52 1978 969 977
66. A. Derksen, and P. Cohen Patterns of fatty acid release from endogenous substrates by human platelet homogenates and membranes J Biol Chem 250 1975 9342 9347
67. M. Milde, R.C. Werthmann, K. von Hayn, and M. Bunemann Dynamics of adenylate cyclase regulation via heterotrimeric G-proteins Biochem Soc Trans 42 2014 239 243
68. A.M. Brummett, A.R. Navratil, J.D. Bryan, and M.D. Woolard Janus kinase 3 activity is necessary for phosphorylation of cytosolic phospholipase A2 and prostaglandin E2 synthesis by macrophages infected with Francisella tularensis live vaccine strain Infect Immun 82 2014 970 982
69. H. Elimam, J. Papillon, T. Takano, and A.V. Cybulsky Complement-mediated activation of calcium-independent phospholipase A2gamma: role of protein kinases and phosphorylation J Biol Chem 288 2013 3871 3885
70. R.J. Flower, and G.J. Blackwell The importance of phospholipase-A2 in prostaglandin biosynthesis Biochem Pharmacol 25 1976 285 291
71. K. Schror, S. Moncada, F.B. Ubatuba, and J.R. Vane Transformation of arachidonic acid and prostaglandin endoperoxides by the guinea pig heart. Formation of RCS and prostacyclin Eur J Pharmacol 47 1978 103 114
72. L.J. Marnett, P. Wlodawer, and B. Samuelsson Co-oxygenation of organic substrates by the prostaglandin synthetase of sheep vesicular gland J Biol Chem 250 1975 8510 8517
73. L.J. Marnett The COXIB experience: a look in the rearview mirror Annu Rev Pharmacol Toxicol 49 2009 265 290
74. K. Kawahara, H. Hohjoh, T. Inazumi, S. Tsuchiya, and Y. Sugimoto Prostaglandin E-induced inflammation: Relevance of prostaglandin E receptors Biochim Biophys Acta 1851 2015 414 421
75. H. Oshima, and M. Oshima The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models J Gastroenterol 47 2012 97 106
76. D. Wang, and R.N. DuBois An inflammatory mediator, prostaglandin E2, in colorectal cancer Cancer J 19 2013 502 510
77. W.E. Smalley, and R.N. DuBois Colorectal cancer and nonsteroidal anti-inflammatory drugs Adv Pharmacol 39 1997 1 20
78. Y.I. Cha, S.H. Kim, D. Sepich, F.G. Buchanan, L. Solnica-Krezel, and R.N. DuBois Cyclooxygenase-1-derived PGE2 promotes cell motility via the G-protein-coupled EP4 receptor during vertebrate gastrulation Genes Dev 20 2006 77 86
79. Korotkova M, Jakobsson PJ. Characterization of mPGES-1 Inhibitors. Basic Clin Pharmacol Toxicol. 2014;114:64-9.
80. B. Samuelsson, R. Morgenstern, and P.J. Jakobsson Membrane prostaglandin E synthase-1: a novel therapeutic target Pharmacol Rev 59 2007 207 224
81. P.J. Jakobsson, S. Thoren, R. Morgenstern, and B. Samuelsson Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target Proc Natl Acad Sci U S A 96 1999 7220 7225
82. K. Watanabe, K. Kurihara, and T. Suzuki Purification and characterization of membrane-bound prostaglandin E synthase from bovine heart Biochim Biophys Acta 1439 1999 406 414
83. T. Tanioka, Y. Nakatani, N. Semmyo, M. Murakami, and I. Kudo Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis J Biol Chem 275 2000 32775 32782
84. N. Tanikawa, Y. Ohmiya, H. Ohkubo, and et al. Identification and characterization of a novel type of membrane-associated prostaglandin E synthase Biochem Biophys Res Commun 291 2002 884 889
85. G. Corso, I. Coletta, and R. Ombrato Murine mPGES-1 3D structure elucidation and inhibitors binding mode predictions by homology modeling and site-directed mutagenesis J Chem Inf Model 53 2013 1804 1817
86. K. Yoshimatsu, D. Golijanin, P.B. Paty, and et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer Clin Cancer Res 7 2001 3971 3976
87. W.Y. Sheng, A. Wyche, T. Lysz, and P. Needleman Prostaglandin endoperoxide E2 isomerase is dissociated from prostaglandin endoperoxide synthetase in the renal cortex J Biol Chem 257 1982 14632 14634
88. A.A. El-Sheikh, J.J. van den Heuvel, J.B. Koenderink, and F.G. Russel Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport J Pharmacol Exp Ther 320 2007 229 235
89. F.G. Russel, J.B. Koenderink, and R. Masereeuw Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules Trends Pharmacol Sci 29 2008 200 207
90. G. Reid, P. Wielinga, N. Zelcer, and et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs Proc Natl Acad Sci U S A 100 2003 9244 9249
91. K. Kleberg, G.M. Jensen, D.P. Christensen, and et al. Transporter function and cyclic AMP turnover in normal colonic mucosa from patients with and without colorectal neoplasia BMC Gastroenterol 12 2012 78
92. M.M. Posada, J.A. Bacon, K.B. Schneck, and et al. Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling Drug Metab Dispos 43 2015 325 334
93. K. Hocherl, C. Schmidt, and M. Bucher COX-2 inhibition attenuates endotoxin-induced downregulation of organic anion transporters in the rat renal cortex Kidney Int 75 2009 373 380
94. N. Ohkura, Y. Shigetani, N. Yoshiba, K. Yoshiba, and T. Okiji Gene expression analysis of membrane transport proteins in normal and lipopolysaccharide-inflamed rat dental pulp J Endod 38 2012 648 652
95. V.R. Holla, M.G. Backlund, P. Yang, R.A. Newman, and R.N. DuBois Regulation of prostaglandin transporters in colorectal neoplasia Cancer Prev Res (Phila) 1 2008 93 99
96. T.J. Kochel, and A.M. Fulton Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE levels in cancer Prostaglandins Other Lipid Mediat 116 2015 99 103
97. S.P. Fink, D.M. Dawson, Y. Zhang, and et al. Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs Carcinogenesis 2014
98. M. Yan, R.M. Rerko, P. Platzer, and et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers Proc Natl Acad Sci U S A 101 2004 17468 17473
99. D. Wang, and R.N. DuBois Urinary PGE-M: a promising cancer biomarker Cancer Prev Res (Phila) 6 2013 507 510
100. H.H. Tai, X. Chi, and M. Tong Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs) Prostaglandins Other Lipid Mediat 96 2011 37 40
101. S.P. Fink, M. Yamauchi, R. Nishihara, and et al. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD) Sci Transl Med 6 2014 233re232
102. K. Guda, S.P. Fink, G.L. Milne, and et al. Inactivating mutation in the prostaglandin transporter gene, SLCO2A1, associated with familial digital clubbing, colon neoplasia, and NSAID resistance Cancer Prev Res (Phila) 7 2014 805 812
103. V. Konya, G. Marsche, R. Schuligoi, and A. Heinemann E-type prostanoid receptor 4 (EP4) in disease and therapy Pharmacol Ther 138 2013 485 502
104. U. Yokoyama, K. Iwatsubo, M. Umemura, T. Fujita, and Y. Ishikawa The prostanoid EP4 receptor and its signaling pathway Pharmacol Rev 65 2013 1010 1052
105. A.M. Fulton, X. Ma, and N. Kundu Targeting prostaglandin E EP receptors to inhibit metastasis Cancer Res 66 2006 9794 9797
106. M.A. Hull, S.C. Ko, and G. Hawcroft Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 3 2004 1031 1039
107. K.M. Khan, P. Kothari, B. Du, A.J. Dannenberg, and D.J. Falcone Matrix metalloproteinase-dependent microsomal prostaglandin E synthase-1 expression in macrophages: role of TNF-alpha and the EP4 prostanoid receptor J Immunol 188 2012 1970 1980
108. K. Subbaramaiah, C. Hudis, S.H. Chang, T. Hla, and A.J. Dannenberg EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange J Biol Chem 283 2008 3433 3444
109. C. Charo, V. Holla, T. Arumugam, and et al. Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor Pancreas 42 2013 467 474
110. H. Katoh, D. Wang, T. Daikoku, H. Sun, S.K. Dey, and R.N. Dubois CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis Cancer Cell 24 2013 631 644
111. D. Wang, H. Wang, J. Brown, and et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer J Exp Med 203 2006 941 951
112. N. Obermajer, J.L. Wong, R.P. Edwards, K. Odunsi, K. Moysich, and P. Kalinski PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells Immunological investigations 41 2012 635 657
113. P.C. Rodriguez, C.P. Hernandez, D. Quiceno, and et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma J Exp Med 202 2005 931 939
114. M. Fujita, G. Kohanbash, W. Fellows-Mayle, and et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells Cancer Res 71 2011 2664 2674
115. P. Sinha, V.K. Clements, A.M. Fulton, and S. Ostrand-Rosenberg Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells Cancer Res 67 2007 4507 4513
116. S. Ostrand-Rosenberg, and P. Sinha Myeloid-derived suppressor cells: linking inflammation and cancer J Immunol 182 2009 4499 4506
117. M. Zeddou, R. Greimers, N. de Valensart, and et al. Prostaglandin E2 induces the expression of functional inhibitory CD94/NKG2A receptors in human CD8+ T lymphocytes by a cAMP-dependent protein kinase A type I pathway Biochem Pharmacol 70 2005 714 724
118. V. Ganapathy, T. Gurlo, H.O. Jarstadmarken, and H. von Grafenstein Regulation of TCR-induced IFN-gamma release from islet-reactive non-obese diabetic CD8(+) T cells by prostaglandin E(2) receptor signaling Int Immunol 12 2000 851 860
119. G. Sconocchia, S. Eppenberger, G.C. Spagnoli, and et al. NK cells and T cells cooperate during the clinical course of colorectal cancer Oncoimmunology 3 2014 e952197
120. Y. Mao, D. Sarhan, A. Steven, B. Seliger, R. Kiessling, and A. Lundqvist Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity Clin Cancer Res 20 2014 4096 4106
121. T. Goto, R.B. Herberman, A. Maluish, and D.M. Strong Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity J Immunol 130 1983 1350 1355
122. S.R. Targan The dual interaction of prostaglandin E2 (PGE2) and interferon (IFN) on NK lytic activation: enhanced capacity of effector-target lytic interactions (recycling) and blockage of pre-NK cell recruitment J Immunol 127 1981 1424 1428
123. N. Kundu, X. Ma, D. Holt, O. Goloubeva, S. Ostrand-Rosenberg, and A.M. Fulton Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function Breast Cancer Res Treat 117 2009 235 242
124. W. Walker, and D. Rotondo Prostaglandin E2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-gamma synthesis Immunology 111 2004 298 305
125. X. Ma, D. Holt, N. Kundu, and et al. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE-mediated immunosuppression and inhibits breast cancer metastasis Oncoimmunology 2 2013 e22647
126. D.M. Holt, X. Ma, N. Kundu, P.D. Collin, and A.M. Fulton Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4 J Immunother 35 2012 179 188
127. D. Holt, X. Ma, N. Kundu, and A. Fulton Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4 Cancer Immunol Immunother 60 2011 1577 1586
128. F. Baratelli, Y. Lin, L. Zhu, and et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells J Immunol 175 2005 1483 1490
129. S. Sharma, S.C. Yang, L. Zhu, and et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer Cancer Res 65 2005 5211 5220
130. T. Bryn, S. Yaqub, M. Mahic, K. Henjum, E.M. Aandahl, and K. Tasken LPS-activated monocytes suppress T-cell immune responses and induce FOXP3+ T cells through a COX-2-PGE2-dependent mechanism Int Immunol 20 2008 235 245
131. M. Mahic, S. Yaqub, C.C. Johansson, K. Tasken, and E.M. Aandahl FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism J Immunol 177 2006 246 254
132. G. O'Callaghan, A. Ryan, P. Neary, C. O'Mahony, F. Shanahan, and A. Houston Targeting the EP1 receptor reduces Fas ligand expression and increases the antitumor immune response in an in vivo model of colon cancer Int J Cancer 133 2013 825 834
133. B.P. Lee, S.C. Juvet, and L. Zhang Prostaglandin E2 signaling through E prostanoid receptor 2 impairs proliferative response of double negative regulatory T cells Int Immunopharmacol 9 2009 534 539
134. V. Apostolopoulos, G.A. Pietersz, A. Tsibanis, and et al. Dendritic cell immunotherapy: clinical outcomes Clin Transl Immunol 3 2014 e21
135. H. Harizi, and N. Gualde Dendritic cells produce eicosanoids, which modulate generation and functions of antigen-presenting cells Prostaglandins Leukot Essent Fatty Acids 66 2002 459 466
136. M.L. Slattery, A. Lundgreen, K.L. Bondurant, and R.K. Wolff Tumor necrosis factor-related genes and colon and rectal cancer Int J Mol Epidemiol Genet 2 2011 328 338
137. N.B. Janakiram, and C.V. Rao Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer Curr Mol Med 9 2009 565 579
138. F.S. Machado, L. Esper, A. Dias, and et al. Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6 J Exp Med 205 2008 1077 1086
139. H. Hackstein, A.E. Morelli, A.T. Larregina, and et al. Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells J Immunol 166 2001 7053 7062
140. T. Chinen, K. Komai, G. Muto, and et al. Prostaglandin E2 and SOCS1 have a role in intestinal immune tolerance Nat Commun 2 2011 190
141. S.W. Rowlinson, B.C. Crews, D.C. Goodwin, C. Schneider, J.K. Gierse, and L.J. Marnett Spatial requirements for 15-(R)-hydroxy-5Z,8Z,11Z, 13E-eicosatetraenoic acid synthesis within the cyclooxygenase active site of murine COX-2. Why acetylated COX-1 does not synthesize 15-(R)-hete J Biol Chem 275 2000 6586 6591
142. S.W. Park, D.S. Heo, and M.W. Sung The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells Cell Oncol (Dordr) 35 2012 1 8
143. R. Ganesh, D.J. Marks, K. Sales, M.C. Winslet, and A.M. Seifalian Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells World J Surg Oncol 10 2012 200
144. L.G. Melstrom, D.J. Bentrem, M.R. Salabat, and et al. Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model Clin Cancer Res 14 2008 6525 6530
145. C. Picado Mechanisms of aspirin sensitivity Curr Allergy Asthma Rep 6 2006 198 202
146. A. Umar Is 15-LOX-1 a tumor suppressor? J Natl Cancer Inst 104 2012 645 647
147. X. Zuo, Z. Peng, Y. Wu, and et al. Effects of gut-targeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice J Natl Cancer Inst 104 2012 709 716
148. K.V. Honn, I.M. Grossi, C.A. Diglio, M. Wojtukiewicz, and J.D. Taylor Enhanced tumor cell adhesion to the subendothelial matrix resulting from 12(S)-HETE-induced endothelial cell retraction FASEB J 3 1989 2285 2293
149. K.V. Honn, D.G. Tang, X. Gao, and et al. 12-lipoxygenases and 12(S)-HETE: role in cancer metastasis Cancer Metastasis Rev 13 1994 365 396
150. P.M. Rothwell, M. Wilson, J.F. Price, J.F. Belch, T.W. Meade, and Z. Mehta Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials Lancet 379 2012 1591 1601
151. V.C. Tam Lipidomic profiling of bioactive lipids by mass spectrometry during microbial infections Semin Immunol 25 2013 240 248
152. V. Evangelista, A. Celardo, G. Dell'Elba, and et al. Platelet contribution to leukotriene production in inflammation: in vivo evidence in the rabbit Thromb Haemost 81 1999 442 448
153. M. Spite, J. Claria, and C.N. Serhan Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases Cell Metab 19 2014 21 36
154. M. Hamberg, J. Svensson, and B. Samuelsson Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins Proc Natl Acad Sci U S A 71 1974 3824 3828
155. J.F. Parkinson Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation Inflamm Allergy Drug Targets 5 2006 91 106
156. Y.M. O'Meara, and H.R. Brady Lipoxins, leukocyte recruitment and the resolution phase of acute glomerulonephritis Kidney Int Suppl 58 1997 S56 S61
157. C.N. Serhan, and K.A. Sheppard Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro J Clin Invest 85 1990 772 780
158. J.G. Filep, T. Khreiss, and L. Jozsef Lipoxins and aspirin-triggered lipoxins in neutrophil adhesion and signal transduction Prostaglandins Leukot Essent Fatty Acids 73 2005 257 262
159. B.D. Levy, C.B. Clish, B. Schmidt, K. Gronert, and C.N. Serhan Lipid mediator class switching during acute inflammation: signals in resolution Nat Immunol 2 2001 612 619
160. F.H. Qiu, P.R. Devchand, K. Wada, and C.N. Serhan Aspirin-triggered lipoxin A4 and lipoxin A4 up-regulate transcriptional corepressor NAB1 in human neutrophils FASEB J 15 2001 2736 2738
161. I.M. Fierro, and C.N. Serhan Mechanisms in anti-inflammation and resolution: the role of lipoxins and aspirin-triggered lipoxins Braz J Med Biol Res 34 2001 555 566
162. C.N. Serhan, R. Yang, K. Martinod, and et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions J Exp Med 206 2009 15 23
163. M. Spite, and C.N. Serhan Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins Circ Res 107 2010 1170 1184
164. N. Krishnamoorthy, P.R. Burkett, J. Dalli, and et al. Cutting edge: maresin-1 engages regulatory T cells to limit type 2 innate lymphoid cell activation and promote resolution of lung inflammation J Immunol 194 2015 863 867
165. C.N. Serhan Pro-resolving lipid mediators are leads for resolution physiology Nature 510 2014 92 101
166. C.N. Serhan, K. Gotlinger, S. Hong, and et al. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes J Immunol 176 2006 1848 1859
167. C.N. Serhan, S. Hong, K. Gronert, and et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals J Exp Med 196 2002 1025 1037
168. S. Hong, K. Gronert, P.R. Devchand, R.L. Moussignac, and C.N. Serhan Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation J Biol Chem 278 2003 14677 14687
169. C.N. Serhan, K. Gotlinger, S. Hong, and M. Arita Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis Prostaglandins Other Lipid Mediat 73 2004 155 172
170. Y.P. Sun, S.F. Oh, J. Uddin, and et al. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation J Biol Chem 282 2007 9323 9334
171. L. Swaim, and R.S. Hillman Aspirin administered to women at 100 mg every other day produces less platelet inhibition than aspirin administered at 81 mg per day: implications for interpreting the women's health study J Thromb Thrombolysis 28 2009 94 100
172. M.G. Sciulli, P. Filabozzi, S. Tacconelli, and et al. Platelet activation in patients with colorectal cancer Prostaglandins Leukot Essent Fatty Acids 72 2005 79 83
173. M. Dovizio, S. Tacconelli, E. Ricciotti, and et al. Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis J Pharmacol Exp Ther 341 2012 242 250
174. I.B. Zavodnik, E. Lapshina, E. Sudnikovich, and et al. Structure, stability, and antiplatelet activity of O-acyl derivatives of salicylic acid and lipophilic esters of acetylsalicylate Pharmacol Rep 61 2009 476 489
175. F. Finamore, F. Priego-Capote, S. Nolli, A. Zufferey, P. Fontana, and J.C. Sanchez Characterisation of the influences of aspirin-acetylation and glycation on human plasma proteins J Proteomics 114 2015 125 135
176. P. Patrignani, S. Tacconelli, E. Piazuelo, and et al. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action J Thromb Haemost 12 2014 1320 1330
177. K.V. Honn, B. Cicone, and A. Skoff Prostacyclin: a potent antimetastatic agent Science 212 1981 1270 1272
178. D.G. Menter, J.S. Hatfield, C. Harkins, and et al. Tumor cell-platelet interactions in vitro and their relationship to in vivo arrest of hematogenously circulating tumor cells Clin Exp Metastasis 5 1987 65 78
179. P.L. Dunn, and R.J. North Resolution of primary murine listeriosis and acquired resistance to lethal secondary infection can be mediated predominantly by Thy-1+ CD4- CD8- cells J Infect Dis 164 1991 869 877
180. Z. Li, F. Yang, S. Dunn, A.K. Gross, and S.S. Smyth Platelets as immune mediators: their role in host defense responses and sepsis Thromb Res 127 2011 184 188
181. A. Umar, M. Boisseau, A. Yusup, H. Upur, B. Begaud, and N. Moore Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model Fundam Clin Pharmacol 18 2004 559 563
182. S. Ogino, P. Lochhead, E. Giovannucci, J.A. Meyerhardt, C.S. Fuchs, and A.T. Chan Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology Oncogene 33 2014 2949 2955
183. S. Ogino, X. Liao, and A.T. Chan Aspirin, PIK3CA mutation, and colorectal-cancer survival N Engl J Med 368 2013 289 290
184. X. Liao, P. Lochhead, R. Nishihara, and et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival N Engl J Med 367 2012 1596 1606
185. J.A. Engelman, L. Chen, X. Tan, and et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nat Med 14 2008 1351 1356
186. Y. Samuels, Z. Wang, A. Bardelli, and et al. High frequency of mutations of the PIK3CA gene in human cancers Science 304 2004 554
187. N. Kothari, R. Kim, R.N. Jorissen, and et al. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation Acta Oncol 2014 1 6
188. X.F. Ye, J. Wang, W.T. Shi, and J. He Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies Br J Cancer 111 2014 2172 2179
189. R. Nishihara, P. Lochhead, A. Kuchiba, and et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status JAMA 309 2013 2563 2571
190. H. Kang, and D. Shibata Direct measurements of human colon crypt stem cell niche genetic fidelity: the role of chance in non-darwinian mutation selection Front Oncol 3 2013 264
191. A.G. Schepers, H.J. Snippert, D.E. Stange, and et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas Science 337 2012 730 735
192. N. Barker, R.A. Ridgway, J.H. van Es, and et al. Crypt stem cells as the cells-of-origin of intestinal cancer Nature 457 2009 608 611
193. G.L. Eastwood, and G.F. Quimby Effect of chronic aspirin ingestion on epithelial proliferation in rat fundus, antrum, and duodenum Gastroenterology 82 1982 852 856
194. M. Djaldetti, and P. Fishman The effect of aspirin on mouse small-intestinal mucosa. Ultrastructural studies Arch Pathol Lab Med 105 1981 144 147
195. J.M. Fischer, A.G. Schepers, H. Clevers, D. Shibata, and R.M. Liskay Occult progression by Apc-deficient intestinal crypts as a target for chemoprevention Carcinogenesis 35 2014 237 246
196. T. Snowsill, N. Huxley, M. Hoyle, and et al. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome Health Technol Assess 18 2014 1 406
197. M.A. McIlhatton, J. Tyler, L.A. Kerepesi, and et al. Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model Cancer Prev Res (Phila) 4 2011 684 693
198. M.L. Slattery, K. Curtin, C. Sweeney, and et al. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer Int J Cancer 120 2007 656 663
199. C. Choudhary, C. Kumar, F. Gnad, and et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions Science 325 2009 834 840
200. S. Marimuthu, R.S. Chivukula, L.F. Alfonso, M. Moridani, F.K. Hagen, and G.J. Bhat Aspirin acetylates multiple cellular proteins in HCT-116 colon cancer cells: Identification of novel targets Int J Oncol 39 2011 1273 1283
201. L.F. Alfonso, K.S. Srivenugopal, T.V. Arumugam, T.J. Abbruscato, J.A. Weidanz, and G.J. Bhat Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells Int J Oncol 34 2009 597 608
202. A.K. Garg, G.N. Hortobagyi, B.B. Aggarwal, A.A. Sahin, and T.A. Buchholz Nuclear factor-kappa B as a predictor of treatment response in breast cancer Curr Opin Oncol 15 2003 405 411
203. D.L. DeWitt, E.A. el-Harith, S.A. Kraemer, and et al. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases J Biol Chem 265 1990 5192 5198
204. M. Barkett, D. Xue, H.R. Horvitz, and T.D. Gilmore Phosphorylation of IkappaB-alpha inhibits its cleavage by caspase CPP32 in vitro J Biol Chem 272 1997 29419 29422
205. M.R. Pan, H.C. Chang, and W.C. Hung Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases Cell Signal 20 2008 1134 1141
206. S.D. Emerson, V.S. Madison, R.E. Palermo, and et al. Solution structure of the Ras-binding domain of c-Raf-1 and identification of its Ras interaction surface Biochemistry 34 1995 6911 6918
207. F. Yan, Q. He, X. Hu, and et al. Direct regulation of caspase3 by the transcription factor AP2alpha is involved in aspirininduced apoptosis in MDAMB453 breast cancer cells Mol Med Rep 7 2013 909 914
208. D. Xia, D. Wang, S.H. Kim, H. Katoh, and R.N. DuBois Prostaglandin E2 promotes intestinal tumor growth via DNA methylation Nat Med 18 2012 224 226
209. Y. Kim, K. Kim, D. Park, and et al. DNA methyl transferase I acts as a negative regulator of allergic skin inflammation Mol Immunol 53 2013 1 14
210. G.A. Spitz, C.M. Furtado, M. Sola-Penna, and P. Zancan Acetylsalicylic acid and salicylic acid decrease tumor cell viability and glucose metabolism modulating 6-phosphofructo-1-kinase structure and activity Biochem Pharmacol 77 2009 46 53
211. L.M. Carlson, A. Rasmuson, H. Idborg, and et al. Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma Carcinogenesis 34 2013 1081 1088
212. E. Allen, I.B. Walters, and D. Hanahan Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition Clinical cancer research: an official journal of the American Association for Cancer Research 17 2011 5299 5310
213. J.M. Fischer, A.J. Miller, D. Shibata, and R.M. Liskay Different phenotypic consequences of simultaneous versus stepwise Apc loss Oncogene 31 2012 2028 2038
214. G.A. Kune, S. Kune, and L.F. Watson Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study Cancer research 48 1988 4399 4404
215. R.F. Logan, M.J. Grainge, V.C. Shepherd, N.C. Armitage, and K.R. Muir Aspirin and folic acid for the prevention of recurrent colorectal adenomas Gastroenterology 134 2008 29 38
216. J. Burn, D.T. Bishop, P.D. Chapman, and et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis Cancer Prev Res (Phila) 4 2011 655 665
217. P.M. Rothwell, M. Wilson, C.E. Elwin, and et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials Lancet 376 2010 1741 1750
218. Cancer Prevention Programme (CaPP) 3. http://www.capp3.org/resources.aspx2015.
219. M. Dovizio, S. Tacconelli, C. Sostres, E. Ricciotti, and P. Patrignani Mechanistic and pharmacological issues of aspirin as an anticancer agent Pharmaceuticals (Basel) 5 2012 1346 1371
220. W.B. Armstrong, T.H. Taylor, and F.L. Meyskens Jr Point: surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers Cancer Epidemiol Biomarkers Prev 12 2003 589 592
221. M.M. Bertagnolli Colorectal cancer prevention studies: the importance of defining disease risk Ann Surg Oncol 10 2003 829 830
222. C.A. Elmets, J.L. Viner, A.P. Pentland, and et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial J Natl Cancer Inst 102 2010 1835 1844
223. N.R. Cook, I.M. Lee, S.M. Zhang, M.V. Moorthy, and J.E. Buring Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial Annals of internal medicine 159 2013 77 85
224. N.R. Cook, I.M. Lee, J.M. Gaziano, and et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial Jama 294 2005 47 55
225. J.A. Baron, R.S. Sandler, R.S. Bresalier, and et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas Gastroenterology 131 2006 1674 1682
226. Aspirin in Reducing Events in Elderly (ASPREE). 2015.
227. R. Ali, H.C. Toh, and W.K. Chia The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer - the ASCOLT study: study protocol for a randomized controlled trial Trials 12 2011 261
228. Add-Aspirin Trial. http://www.addaspirintrial.org.
229. PCORI. Optimal Aspirin Dose for Patients with Coronary Artery Disease 2015.
230. Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE). http://www.arrive-study.com/en/study.cfm2015.
231. A Study of Cardiovascular Events iN Diabetes (ASCEND). http://www.ctsu.ox.ac.uk/ascend/%5D.
232. G. De Berardis, M. Sacco, V. Evangelista, and et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins Trials 8 2007 21